A novel combination therapy of arginine deiminase and an arginase inhibitor targeting arginine metabolism in the tumor and immune microenvironment

Biochemistry, Genetics and Molecular Biology

• Arginine 100%
• Metabolic Pathway 100%
• Arginine Deiminase 100%
• Arginase 100%
• Immunocompetent Cell 80%
• Tumor Progression 60%
• RNA Sequencing 40%
• T Cell 40%
• Dendritic Cell 40%
• CD8 40%
• Mouse 20%
• Cancer Cell 20%
• Monocyte 20%
• Immune Response 20%
• Cell Activation 20%
• Cell Cycle 20%
• Molecular Weight 20%
• Anticancer 20%
• Biogenesis 20%
• Ribosome Biogenesis 20%
• S100A9 20%
• Citrulline 20%
• Cytotoxic T Cell 20%
• Ribonucleoprotein 20%
• Argininosuccinate Synthase 20%

Immunology and Microbiology

• Immunocompetent Cell 100%
• Arginine Deiminase 100%
• Tumor Cell 75%
• Biogenesis 50%
• Dendritic Cell 50%
• RNA Sequencing 50%
• Mouse 25%
• Cancer Cell 25%
• Monocyte 25%
• Cytotoxic T Cell 25%
• Immune Response 25%
• Molecular Weight 25%
• Cytotoxic T-Cell 25%
• CD8 25%
• Immunosuppressive Drug 25%
• T Cell Activation 25%
• Ribosome 25%
• Cell Cycle 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Arginase 100%
• Arginine Deiminase 100%
• Neoplasm 100%
• Combination Therapy 100%
• Arginine 100%
• Norvaline 41%
• Polyethylene Glycol 41%
• Malignant Neoplasm 25%
• Tumor Growth 25%
• CD8 Antigen 16%
• Macrogol 8%
• Mouse 8%
• Melanoma 8%
• Immunosuppressive Agent 8%
• Pegargiminase 8%
• Ribonucleoprotein 8%
• Argininosuccinate Synthase 8%
• Citrulline 8%